Disease · MONDO_0011429

juvenile idiopathic arthritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. juvenile idiopathic arthritis. Diseases, record MONDO_0011429. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011429

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: juvenile idiopathic arthritis; Open Targets
Open Targets ID: MONDO_0011429; Open Targets
Other names: Arthritis (juvenile idiopathic), Arthritis, Juvenile Rheumatoid, JIA, Juvenile chronic arthritis, Juvenile chronic arthritis (disorder), Juvenile idiopathic arthritis (disorder), Juvenile rheumatoid a., Juvenile rheumatoid arthritis (disorder), Juvenile rheumatoid arthritis NOS (disorder), Juvenile rheumatoid arthritis, NOS, Juvenile seropositive polyarthritis, breast myoepithelial carcinoma, chronic childhood arthritis, juvenile arthritis, juvenile rheumatoid arthritis, rheumatoid arthritis, systemic juvenile, susceptibility to; Open Targets
Disease Ontology: DOID:676; Disease Ontology
MeSH: D001171; MeSH
NCI Thesaurus: C114357; NCI Thesaurus
Orphanet: ORPHA:92; Orphanet
Highest stage of its drugs: Approval, for 26 of its 53 drugs, from DailyMed, EMA Human Drugs and PMDA; Open Targets

Drugs53

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ETANERCEPT	CHEMBL1201572	Protein	Approval	DailyMed and EMA Human Drugs	23	17	16	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Approval	DailyMed and EMA Human Drugs	19	12	12	Drugs and targets
TOCILIZUMAB	CHEMBL1237022	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	18	10	10	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Approval	DailyMed	123	5	4	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Approval	EMA Human Drugs and PMDA	21	5	5	Drugs and targets
ABATACEPT	CHEMBL1201823	Protein	Approval	DailyMed and EMA Human Drugs	6	4	4	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Approval	DailyMed	54	3	3	Drugs and targets
GOLIMUMAB	CHEMBL1201833	Antibody	Approval	EMA Human Drugs	5	3	3	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	19	2	2	Drugs and targets
IBUPROFEN	CHEMBL521	Small molecule	Approval	DailyMed	9	2	1	Drugs and targets

1 to 10 of 53

See all 53 drugs

Targets39

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	9	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS1	Cyclooxygenase	6	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
TNF	Tumor necrosis factor	5	TNF-alpha inhibitor	Approval	https://conductscience.org/library/genes/7124	Drugs and targets
JAK1	Janus Kinase (JAK)	4	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	4	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
IL17A	Interleukin-17A	3	Interleukin 17A inhibitor	Approval	https://conductscience.org/library/genes/3605	Drugs and targets
JAK3	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Phase 3	https://conductscience.org/library/genes/3718	Drugs and targets
TYK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor	Phase 3	https://conductscience.org/library/genes/7297	Drugs and targets
ALOX5	Polyunsaturated fatty acid 5-lipoxygenase	2	Arachidonate 5-lipoxygenase inhibitor	Approval	https://conductscience.org/library/genes/240	Drugs and targets

1 to 10 of 39

See all 39 targets

Trials78

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00688545	Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis		275	2013-07-19	Arthritis, Juvenile Rheumatoid	CELECOXIB	Its record names the disease	ClinicalTrials.gov
NCT05000216	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Phase 2	258	2025-08-22	Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)	ELASOMERAN, TOZINAMERAN	Its record names the disease	ClinicalTrials.gov
NCT02592434	Efficacy Study Of Tofacitinib In Pediatric JIA Population	Phase 3	225	2020-02-21	Juvenile Idiopathic Arthritis	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT01844518	Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)	Phase 3	219	2016-03-24	Active Polyarticular Juvenile Idiopathic Arthritis	ABATACEPT	Its record names the disease	ClinicalTrials.gov
NCT00095173	BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis	Phase 3	214	2017-01-18	Juvenile Rheumatoid Arthritis	ABATACEPT	Its record names the disease	ClinicalTrials.gov
NCT00807846	A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects	Phase 4	201	2015-11-11	Arthritis, Juvenile Rheumatoid	CELECOXIB, NAPROXEN	Its record names the disease	ClinicalTrials.gov
NCT01550003	Pediatric Arthritis Study of Certolizumab Pegol	Phase 3	193	2024-10-23	Polyarticular-course Juvenile Idiopathic Arthritis (JIA)	CERTOLIZUMAB PEGOL	Its record names the disease	ClinicalTrials.gov
NCT00988221	A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis	Phase 3	188	2012-11-01	Juvenile Idiopathic Arthritis	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01230827	A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)	Phase 3	173	2014-09-29	Juvenile Idiopathic Arthritis	GOLIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00048542	Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)	Phase 3	171	2010-01-11	Arthritis, Juvenile Idiopathic	ADALIMUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 78

See all 78 trials

Comparisons in its trials23

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Celecoxib vs nsNSAIDs: serious adverse events	2 of 68	9 of 225	293	NCT00688545	Trial comparisons
SC Abatacept Ages 6 to 17 vs SC Abatacept Ages 2 to 5: deaths from any cause	0 of 173	0 of 46	219	NCT01844518	Trial comparisons
SC Abatacept Ages 6 to 17 vs SC Abatacept Ages 2 to 5: serious adverse events	18 of 173	6 of 46	219	NCT01844518	Trial comparisons
SC Abatacept Ages 6 to 17 vs SC Abatacept Ages 2 to 5: Number of Participants With Positive Immunogenicity Response in the Cumulative Period	8 of 172	7 of 46	218	NCT01844518	Trial comparisons
Celecoxib vs Naproxen: serious adverse events	0 of 100	1 of 98	198	NCT00807846	Trial comparisons
Celecoxib vs Naproxen: Number of Participants With >= 30% Improvement in the Parent's Global Assessment of Overall Well-being at Week 6/Final Visit.	47 of 98	54 of 98	196	NCT00807846	Trial comparisons
Reduced CZP Dose vs Original CZP Dose: Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 16	69 of 84	77 of 97	181	NCT01550003	Trial comparisons
Adalimumab + MTX vs Adalimumab: Number of Subjects Meeting Pediatric American College of Rheumatology 30% (PedACR30) Response Criteria at the End of the Open-Label Lead-In Phase	80 of 85	64 of 86	171	NCT00048542	Trial comparisons
Celecoxib vs Naproxen: Number of Participants With >= 30% Improvement in the Participant's Global Assessment of Overall Well-being at Week 6/Final Visit.	33 of 75	45 of 83	158	NCT00807846	Trial comparisons
Reduced CZP Dose vs Original CZP Dose: Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 48	58 of 72	47 of 60	132	NCT01550003	Trial comparisons

1 to 10 of 23

See all 23 comparisons in its trials

Papers from its trials58

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42439289	RESULT	1	PubMed
21623000	RESULT	1	PubMed
21173013	RESULT	1	PubMed
20669280	RESULT	1	PubMed
19714630	RESULT	1	PubMed
19664754	RESULT	1	PubMed
17763439	RESULT	1	PubMed
14571231	RESULT	1	PubMed
11739431	RESULT	1	PubMed
42011511	DERIVED	2	PubMed

1 to 10 of 58

See all 58 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011429

GET https://conductscience.org/api/diseases/v1/MONDO_0011429/drugs?page=2

API reference For AI assistants